Plasma drug activity assay for treatment optimization in tuberculosis patients. - Test2 - elhamkhani - TriplyDB

Plasma drug activity assay for treatment optimization in tuberculosis patients.

Plasma drug activity assay for treatment optimization in tuberculosis patients.

http://www.wikidata.org/entity/Q30426583

about

Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania.Improvement in plasma drug activity during the early treatment interval among Tanzanian patients with multidrug-resistant tuberculosis.The Influence of Mining and Human Immunodeficiency Virus Infection Among Patients Admitted for Retreatment of Tuberculosis in Northern Tanzania.Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis Understanding pharmacokinetics to improve tuberculosis treatment outcome.Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA.Complete genome sequence of the frog pathogen Mycobacterium ulcerans ecovar Liflandii Review of evidence for measuring drug concentrations of first-line antitubercular agents in adults.Treatment of Tuberculosis. A Historical Perspective.Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?Plasma Levels of Rifampin Correlate with the Tuberculosis Drug Activity Assay.The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes

P2860

Q28487970-8BCE0336-668E-474B-96D8-8409F03571C3 Q28545109-C83941A9-6CC7-48C7-B82C-23C5B65492DC Q30279294-A2EAAA1E-EED3-4AF4-B2A3-0204AD27F4EE Q30411475-B8B5AF7D-A90F-450C-B7F7-1840C363FB74 Q30411703-8BFCB567-B832-4CBE-B807-9DF3B19FBA89 Q30415746-4D023799-2735-44B5-86EA-B7EE2BCB3292 Q34314997-76FE63E3-591B-4883-BD4E-4093FEEEE663 Q38244769-D339A9AB-F687-473F-B926-99D1ABCA10FA Q46014832-5E263654-E76C-4C3E-A20C-9B239128D5C9 Q47332682-696A447B-81FD-4C95-A463-E8EE7FDE0196 Q52684511-AA20F038-BC71-470B-AD93-3FD0282E7C9B Q57152709-4258B033-2917-44B1-8629-EBC14E5812AC

P2860

Plasma drug activity assay for treatment optimization in tuberculosis patients.

http://www.wikidata.org/entity/Q30426583

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Plasma drug activity assay for treatment optimization in tuberculosis patients.

@ast

Plasma drug activity assay for treatment optimization in tuberculosis patients.

@en

type

label

Plasma drug activity assay for treatment optimization in tuberculosis patients.

@ast

Plasma drug activity assay for treatment optimization in tuberculosis patients.

@en

prefLabel

Plasma drug activity assay for treatment optimization in tuberculosis patients.

@ast

Plasma drug activity assay for treatment optimization in tuberculosis patients.

@en

P1433

Q30426583-072F74A4-086B-4983-AD66-5323096A6399

P1476

Q30426583-13C0F855-166D-413E-8174-299C0EDD44A2

P2093

Q30426583-00A299B7-8835-4F7B-A426-F86F9FED861B

Q30426583-4E06D69A-D664-4962-A202-C064F68F5B10

Q30426583-7F1530FC-2AD2-4474-9CCE-8A47026AE201

Q30426583-A65C9287-B72D-4DE7-B163-85B669888501

Q30426583-E31B1969-DC63-42DE-82B1-820591EA5D07

Q30426583-E7B3499A-AF5E-49D4-841C-50C392C301D8

P2860

Q30426583-04CACEF8-D118-4D31-A3B7-0A2F22351B09

Q30426583-0CB422E3-152E-41D3-81FD-70AC6D389790

Q30426583-0EC8614C-3CE4-4008-8816-BA7B34DE2548

Q30426583-142410B1-860E-4BF3-B189-8A44A3AE4092

Q30426583-27F0E35A-8563-4F5F-8E76-03F2E18B4049

Q30426583-30C3A817-2D61-4863-BCED-F27F998B7E33

Q30426583-33B4216C-48E1-4DC1-A28D-46B395A147B6

Q30426583-4FFD4CAC-CD9F-44C2-9683-3234157BB1C7

Q30426583-6055DCBF-AA79-45B2-B593-8B225E967FEC

Q30426583-75D97D36-8525-4FC1-9C8D-036D07944B68

P304

Q30426583-AA1551B3-9546-4D1B-8E05-345210A329D4

P31

Q30426583-5307C515-2CDD-4B6A-B928-D9CFAA259DEE

P356

Q30426583-1E48BA05-62B0-4DEE-9E4C-9A39D67F24A5

P407

Q30426583-5EE217F3-703E-47CE-9AF7-193D2A99880F

P433

Q30426583-FADFE203-2CAB-40F8-90D0-490A27BD6DC7

P478

Q30426583-B35E794B-4CE1-440B-8731-0B59366959BF

P50

Q30426583-945C3F0E-5F33-479D-8E13-C3CA1B8AADF1

Q30426583-9F74B80D-33BF-45D7-8CB4-DC87AE8C6BBD

Q30426583-D2E749E8-0987-45AC-A872-310B15A3AD41

Q30426583-E0D86B06-3888-499F-89B3-89D55C431B1B

P577

Q30426583-CAB8B5A7-B948-4596-89A3-66F9A0C8A2B2

P698

Q30426583-03C64142-D75A-4284-82D3-2722D3D941E2

P921

Q30426583-1B2AF5F9-FF53-4EC2-BCFD-6C892F097776

P932

Q30426583-277D6ADC-4FA3-47F7-AD5E-E7E6E21BF55B

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Plasma drug activity assay for treatment optimization in tuberculosis patients.

@en

P2093

Charles Mtabho

http://www.w3.org/2001/XMLSchema#string

Gibson S Kibiki

http://www.w3.org/2001/XMLSchema#string

Norah Ndusilo

http://www.w3.org/2001/XMLSchema#string

Rob E Aarnoutse

http://www.w3.org/2001/XMLSchema#string

Solomon Mwaigwisya

http://www.w3.org/2001/XMLSchema#string

Stellah Mpagama

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.

Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA.

Tuberculosis and diabetes mellitus: convergence of two epidemics.

Priorities for tuberculosis research: a systematic review.

Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids.

Therapeutic drug monitoring in the treatment of tuberculosis.

Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.

Treatment of multidrug-resistant tuberculosis: evidence and controversies.

Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.

P304

5819-5825

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.05561-11

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

Scott K Heysell

P577

2011-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21968363

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

3232779

http://www.w3.org/2001/XMLSchema#string